Blood pressure in persons with haemophilia with a focus on haemophilia-specific risk factors.
blood pressure
haemophilia
hypertension
inhibitors
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
26
05
2022
received:
11
03
2022
accepted:
12
06
2022
pubmed:
1
7
2022
medline:
16
11
2022
entrez:
30
6
2022
Statut:
ppublish
Résumé
Persons with haemophilia (PWH) have a higher prevalence of hypertension compared to the general population, which cannot be explained entirely by the usual cardiovascular risk factors. Neutralizing antibodies (inhibitors) against clotting factors might have some relation to cardiovascular disease in PWH. However, whether inhibitors facilitate hypertension is unknown. We investigated the relationship between hypertension/blood pressure and inhibitors in PWH. Additional goals were to determine the relationships with haemophilia type, race, and viral status. Records were extracted retrospectively for PWH (age ≥18 years) between 2003 and 2014 from four Hemophilia Treatment Centers in North America and included demographics, weight, height, haemophilia type/severity, HCV and HIV infection status, hypertension, use of anti-hypertensive medications, and inhibitor status. We fitted semiparametric generalized additive models (GAMs) to describe adjusted curves of blood pressure (BP) against age. Among 691 PWH, 534 had haemophilia A and 157 had haemophilia B, with a median age of 39 years (range 18 to 79). Forty-four PWH (6.5%) had a history of inhibitors, without evidence for a higher prevalence of hypertension or higher BP. A higher prevalence of hypertension and higher BP were noted for haemophilia A (vs. haemophilia B), coinfection with HCV/HIV (vs. uninfected), or moderate haemophilia (vs. severe haemophilia). While there was no signal to suggest that a history of inhibitors is associated with hypertension, differences based on haemophilia type, severity, and viral infection status were identified, encouraging prospective investigations to better delineate haemophilia-specific risk factors for hypertension.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
977-985Subventions
Organisme : HRSA HHS
ID : H30MC24045
Pays : United States
Organisme : HRSA HHS
ID : H30MC24045
Pays : United States
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Hay CRM, Nissen F, Pipe SW. Mortality in congenital hemophilia A - a systematic literature review. J Thromb Haemost. 2021;19(S1):6-20. https://doi.org/10.1111/jth.15189
Sood SL, Cheng D, Ragni M, et al. A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Adv. 2018;2(11):1325-1333. https://doi.org/10.1182/bloodadvances.2018018226
van de Putte DE, Fischer K, Makris M, et al. Increased prevalence of hypertension in haemophilia patients. Thromb Haemostasis. 2012;108(10):750-755. https://doi.org/10.1160/TH12-05-0313
von Drygalski A, Kolaitis NA, Bettencourt R, et al. Prevalence and risk factors for hypertension in hemophilia. Hypertension. 2013;62(1):209-215. https://doi.org/10.1161/HYPERTENSIONAHA.113.01174
SHARATHKUMAR AA, SOUCIE JM, TRAWINSKI B, GREIST A, SHAPIRO AD. Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia. 2011;17(4):597-604. https://doi.org/10.1111/j.1365-2516.2010.02463.x
WALSH M, MACGREGOR D, STUCKLESS S, BARRETT B, KAWAJA M, SCULLY MF. Health-related quality of life in a cohort of adult patients with mild hemophilia A. J Thromb Haemost. 2008;6(5):755-761. https://doi.org/10.1111/j.1538-7836.2008.02929.x
FOLEY CJ, NICHOLS L, JEONG K, MOORE CG, v RAGNIM. Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost. 2010;8(1):208-211. https://doi.org/10.1111/j.1538-7836.2009.03669.x
BIERE-RAFI S TUINENBURGA, BW HAAK, et al. Factor VIII deficiency does not protect against atherosclerosis. J Thromb Haemost. 2012;10(1):30-37. https://doi.org/10.1111/j.1538-7836.2011.04499.x
Marchesini E, Oliovecchio E, Coppola A, et al. Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population. Haemophilia. 2018;24(1):e6-e10. https://doi.org/10.1111/hae.13379
Lim MY, Pruthi RK. Cardiovascular disease risk factors. Blood Coagul Fibrinolysis. 2011;22(5). https://doi.org/10.1097/MBC.0b013e328345f582
Fransen van de Putte DE, Fischer K, Makris M, et al. Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thromb Haemost. 2013;109(01):16-23. https://doi.org/10.1160/TH12-05-0332
Barnes RFW, Cramer TJ, Sait AS, Kruse-Jarres R, Quon DVK, von Drygalski A. The Hypertension of Hemophilia Is Not Explained by the Usual Cardiovascular Risk Factors: results of a Cohort Study. Int J Hypertens. 2016;2016:2014201. https://doi.org/10.1155/2016/2014201
SIBONI SM, MANNUCCI PM, GRINGERI A, et al. Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Haemost. 2009;7(5):780-786. https://doi.org/10.1111/j.1538-7836.2009.03318.x
Biere-Rafi S, Baarslag M, Peters M, et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemostasis. 2011;105(02):274-278. https://doi.org/10.1160/TH10-07-0460
Lövdahl S, Henriksson KM, Baghaei F, Holmström M, Berntorp E, Astermark J. Hypertension and cardiovascular diseases in Swedish persons with haemophilia - A longitudinal registry study. Thromb Res. 2019;181:106-111.
Sun HL, Yang M, Sait AS, von Drygalski A, Jackson S. Haematuria is not a risk factor of hypertension or renal impairment in patients with haemophilia. Haemophilia. 2016;22(4):549-555. https://doi.org/10.1111/hae.12921
Holme PA, Combescure C, Tait RC, Berntorp E, Rauchensteiner S, de Moerloose P. Hypertension, haematuria and renal functioning in haemophilia - a cross-sectional study in Europe. Haemophilia. 2016;22(2):248-255. https://doi.org/10.1111/hae.12847
Gopal S, Barnes RF, Quon Dv, Sun HWL, Jackson S, von Drygalski A. Blood pressure in haemophilia and its relation to clotting factor usage. J Haemophilia Pract. 2019;6(1):42-50.
Barnes RFW, Cramer TJ, Hughes TH, von Drygalski A. The hypertension of hemophilia is associated with vascular remodeling in the joint. Microcirculation. 2017;24(7).
SARTORI MT, BILORA F, ZANON E, et al. Endothelial dysfunction in haemophilia patients. Haemophilia. 2008;14(5):1055-1062. https://doi.org/10.1111/j.1365-2516.2008.01808.x
Zwagemaker AF, Gouw SC, Jansen JS, et al. Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis. Blood. 2021;138(26):2853-2873. https://doi.org/10.1182/blood.2021011849
Lattanzi S, Silvestrini M. Blood pressure in acute intra-cerebral hemorrhage. Ann Transl Med. 2016;4(16):320-320. 10.21037/atm.2016.08.04
Pickering TG, Hall JE, Appel LJ, et al. Recommendations Experimental, for blood pressure measurement in humans and A, animals: part 1: blood pressure measurement in humans: professional, statement for professionals from the Subcommittee of Association, and Public Education of the American Heart. Circulation. 2005;111(5):697-716.
Hastie T, Tibshirani R. Generalized Additive Models. Chapman and Hall, New York; 1990.
Sait AS, Kuo A, Bettencourt R, Bergstrom J, Allison M, von Drygalski A. Risk assessment for coronary heart disease in patients with haemophilia: a single centre study in the United States. Haemophilia. 2014;20(6):763-770. https://doi.org/10.1111/hae.12472
Pandey B, Barnes RFW, Sun H(Linda, et al. Risk of diabetes in haemophilia patients compared to clinic and non-clinic control cohorts. Haemophilia. 2022;28(3):445-452. https://doi.org/10.1111/hae.14515
Lim MY, Cheng D, Recht M, Kempton CLKN. Inhibitors and mortality in persons with nonsevere hemophilia A in the United States. Blood Adv. 2020;4(19):4739-4747.
Walsh CE, Soucie JMMCUSHTCN. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol. 2015;90(5):400-405.
Boylan B, Rice AS, Neff AT, Manco-Johnson MJ, Kempton CL, Miller CH, HIRSI. Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay. J Thromb Haemost. 2016;14(10):1931-1940.
Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia. 1996;2(1):28-31.
Ekholm M, Kahan T. The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19. Front Pharmacol. 2021;12:640185. https://doi.org/10.3389/fphar.2021.640185
Petta S, Maida M, Macaluso FS, et al. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: a Meta-Analysis of Observational Studies. Gastroenterology. 2016;150(1):145-155.e4. https://doi.org/10.1053/j.gastro.2015.09.007
Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: national Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief. 2013;133:1-8.
He J, Zhu Z, Bundy JD, Dorans KS, Chen J, Hamm LL. Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999-2018. JAMA. 2021;326(13):1286. https://doi.org/10.1001/jama.2021.15187
Peters SAE, Muntner P, Woodward M. Sex Differences in the Prevalence of, and Trends in, Cardiovascular Risk Factors, Treatment, and Control in the United States, 2001 to 2016. Circulation. 2019;139(8):1025-1035. https://doi.org/10.1161/CIRCULATIONAHA.118.035550
Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication Adherence and Blood Pressure Control: a Scientific Statement From the American Heart Association. Hypertension. 2022;79(1):e1-e14. https://doi.org/10.1161/HYP.0000000000000203
Lo GH, McAlindon TE, Katz JN, et al. Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. Clin Rheumatol. 2017;36(9):2121-2128. https://doi.org/10.1007/s10067-017-3656-z
Wen CY, Chen Y, Tang HL, Yan CH, Lu WW, Chiu KY. Bone loss at subchondral plate in knee osteoarthritis patients with hypertension and type 2 diabetes mellitus. Osteoarthr Cartil. 2013;21(11):1716-1723.
Hussain SM, Dawson C, Wang Y, et al. Vascular Pathology and Osteoarthritis: a Systematic Review. J Rheumatol. 2020;47(5):748-760.